source
- Researchers suspect Exelixis used a minor tweak to cabozantinib to sidestep patent cliffExelixis' 2025 financial results highlighted the importance of its drug cabozantinib, which has been a major revenue source for the company. A group of analysts argue that the company introduced a…
- Deerfield-backed Boulevard Bio raises $65 million and unveils three autoimmune drug candidatesBoulevard Bio, a New York‑based biotech focused on B‑cell biology, announced it has emerged from stealth with $65 million in financing from Deerfield Management. The funding supports the developmen…